Treatment for Hemophilia A

Phase-Based Progress Estimates
University of Alberta, Edmonton, CanadaHemophilia A+1 More
Any Age
All Sexes
What conditions do you have?

Study Summary

This trial will assess the impact of adopting population PK (popPK) based tailored prophylaxis in clinical practice, including proportion of patients eligible for tailoring, and encountered barriers.

Eligible Conditions
  • Hemophilia A
  • Hemophilia B

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

2 Primary · 7 Secondary · Reporting Duration: Measured at study enrollment and at 2 years at study completion.

Month 6
Change in patient quality of life
Change in physical activity
Year 2
Change in joint function
Month 12
Assessment of the predictive performance of the WAPPS-Hemo clinical calculator
Year 1
Feasibility and acceptability of the WAPPS-Hemo based prophylaxis tailoring
Year 2
Consumption of factor concentrates
Year 2
Adherence to prescribed regimen
Year 2
Annualized Bleeding Rate (ABR) pre and post-tailoring implementation
Year 2
Characteristics of reported bleeds

Trial Safety

Trial Design

0 Treatment Group

600 Total Participants · 0 Treatment Group

Primary Treatment: Treatment · No Placebo Group · N/A

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: measured at study enrollment and at 2 years at study completion.

Who is running the clinical trial?

McMaster UniversityLead Sponsor
823 Previous Clinical Trials
1,731,832 Total Patients Enrolled
2 Trials studying Hemophilia A
1,400 Patients Enrolled for Hemophilia A
Alfonso Iorio, MD, PhD, FRCPCPrincipal InvestigatorMcMaster University

Eligibility Criteria

Age Any Age · All Participants · 3 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You are taking a medication to prevent bleeding episodes.

Frequently Asked Questions

In which geographical areas is this experiment being implemented?

"This trial is currently running at 8 locations across Canada, the most prominent being University of British Columbia in Vancouver, University of Calgary in Calgary and University of Alberta." - Anonymous Online Contributor

Unverified Answer

Has recruitment commenced for this experiment?

"Affirmative. Information hosted on confirms that the study, which was initially circulated on July 24th 2019, is actively seeking participants. 600 individuals must be enrolled from 6 different medical sites." - Anonymous Online Contributor

Unverified Answer

What is the scope of participants taking part in this clinical trial?

"Affirmative, according to data from this trial is presently recruiting participants. It was first announced on July 24th 2019 and had its most recent update on September 17th 2021. 600 individuals need to be enrolled at 6 various sites for the study's success." - Anonymous Online Contributor

Unverified Answer

What is the primary objective of this investigation?

"This research project will be evaluated at intervals of 3-6 months, from enrolment to completion. The primary objective is to assess Annualized Bleeding Rate (ABR) before and after the implementation of tailoring strategies. Secondary objectives include assessing changes in joint function with Hemophilia Joint Health Score (HJHS), tracking adherence to prescribed regimens, and evaluating the predictive performance of WAPPS-Hemo clinical calculator through comparing predicted and observed post-infusion levels." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.